echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Stroke: Time is the brain: Stroke, the shorter the hospital admission-thrombolysis time, the prognosis is significantly improved

    Stroke: Time is the brain: Stroke, the shorter the hospital admission-thrombolysis time, the prognosis is significantly improved

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Intravenous TPA (tissue-type plasma protein activator) is still the only medical reperfusion therapy to improve the prognosis of patients with acute ischemic stroke , and its benefit is highly related to time
    .

    Stroke


    The US National Guidelines set door-to-needle (DTN, admission to thrombolysis) goals, but historically, these goals are usually not achieved in routine practice
    .


    Goal




    Plan for the first and second stages of stroke
    .


    In addition, clinical results were evaluated, including mortality, symptomatic intracranial hemorrhage, discharge destination, functional results at discharge, and overall TPA usage before and after the implementation of the "Target: Stroke" program in the first two phases


    Among the 154 221 patients who received tPA within 3 hours of the onset of stroke symptoms (median age 72 years, 50.


    1% women), the median DTN time was 78 minutes before the intervention (interquartile range, 60-98) Reduced to 66 minutes (51-87) in the first stage, and 50 minutes (37-66) in the second stage (P<0.
    001)


    The proportion of patients with DTN ≤ 60 minutes increased from 26.


    4% to 42.
    7% to 68.
    6% (P<0.
    001)


    Compared with the pre-intervention, the hospitals in the second intervention (2014-2018) achieved a higher TPA usage rate (11.
    7% vs.
    5.
    6%; adjusted odds ratio, 2.
    43[95%CI, 2.
    31-2.
    56]) , The hospital mortality rate is lower (6.
    0% vs.
    10.
    0%; adjusted odds ratio, 0.
    69 [0.
    64-0.
    73]), and fewer bleeding complications (3.
    4% vs.
    5.
    5%; adjusted odds ratio, 0.
    68[ 0.
    62-0.
    74]), and a higher rate of discharge home (49.
    6% vs.
    35.
    7%; adjusted odds ratio, 1.
    43[1.
    38-1.
    50])
    .

    Similar results were found in a sensitivity analysis of 18,501 patients who received TPA within 4.
    5 hours of the onset of symptoms
    .

    The important significance of this study is that the timeliness of the start of thrombolytic therapy is greatly improved, and the increase in thrombolytic therapy is related to the improvement of clinical results
    .


    Original Source:


    The timeliness of initiation of thrombolytic therapy is greatly improved, and the increase in thrombolytic therapy is related to the improvement of clinical results
    .
    Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.